Biotech Company
ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) announced on Tuesday that it has issued a narrated commentary on key lessons from this year's Alzheimer's Association International Conference (AAIC 2018). PMN noted that clinical trials indicate that selective targeting of toxic starch-like proteins called
amyloid-beta oligomers that are deposited in human tissues is critical for therapeutic efficacy.
More information can be found
here.
The Company was in the news last week when it issued
a white paper at AAIC 2018 on the caused behind amyloid-beta oligomers in the development and progression of Alzheimer's disease and the importance of neutralizing its toxicity.
FULL DISCLOSURE: ProMIS Neurosciences Inc.is a paid client of Stockhouse Publishing.